Zhaoke Ophthalmology Ltd. (HK:6622)
:6622
Want to see HK:6622 full AI Analyst Report?
Top Page
Zhaoke Ophthalmology Ltd.
(6622)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$2.50
▼(-21.14% Downside)
Action:Reiterated
Date:04/28/26
The score is primarily held back by persistent losses, unstable revenue trends, negative gross profit in 2025, and ongoing cash burn, which together imply continued funding and execution risk. Technical indicators add a modest headwind with the stock trading below key longer-term moving averages and weak momentum. A relatively moderate leverage profile and sizeable equity provide some support, but not enough to offset the operating and cash flow weakness.
Positive Factors
Supportive balance sheet
The company’s balance sheet shows modest debt and a sizable equity base, providing a meaningful capital cushion against operating losses. That structural strength gives management runway to execute R&D and commercialization without immediate solvency pressure, lowering short-term funding risk.
Negative Factors
Persistent losses and negative gross profit
Negative gross profit indicates product or COGS structure currently cannot cover direct costs, not just overhead. Persistent operating and net losses erode shareholder value and signal the core business model has not yet reached unit economics required for sustainable profitability absent structural changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Supportive balance sheet
The company’s balance sheet shows modest debt and a sizable equity base, providing a meaningful capital cushion against operating losses. That structural strength gives management runway to execute R&D and commercialization without immediate solvency pressure, lowering short-term funding risk.
Read all positive factors
Zhaoke Ophthalmology Ltd. (6622) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.45B
Dividend YieldN/A
Average Volume (3M)1.25M
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth-53.85%
EPS Growth12.23%
CountryHK
Employees294
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding548,749,000
10 Day Avg. Volume1,172,850
30 Day Avg. Volume1,251,992
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)0.92
Price to Sales (P/S)46.69
P/FCF Ratio-5.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)HK$421.50M
Zhaoke Ophthalmology Ltd. Business Overview & Revenue Model
Company Description
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that co...
How the Company Makes Money
null...
Zhaoke Ophthalmology Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 31.15M | 69.32M | 18.75M | 0.00 | 0.00 |
| Gross Profit | -32.57M | 51.80M | 14.25M | 0.00 | 0.00 |
| EBITDA | -215.45M | -251.23M | -327.86M | -384.55M | -377.53M |
| Net Income | -203.57M | -237.49M | -385.04M | -407.32M | -2.13B |
Balance Sheet | |||||
| Total Assets | 1.94B | 2.24B | 2.42B | 2.57B | 2.61B |
| Cash, Cash Equivalents and Short-Term Investments | 1.30B | 1.19B | 1.46B | 1.73B | 2.14B |
| Total Debt | 292.48M | 238.59M | 238.03M | 131.93M | 37.03M |
| Total Liabilities | 359.58M | 343.44M | 372.02M | 222.25M | 109.92M |
| Stockholders Equity | 1.58B | 1.90B | 2.05B | 2.35B | 2.50B |
Cash Flow | |||||
| Free Cash Flow | -265.04M | -297.79M | -418.93M | -569.60M | -339.63M |
| Operating Cash Flow | -260.20M | -253.72M | -323.66M | -331.05M | -245.14M |
| Investing Cash Flow | 109.11M | -116.45M | -75.77M | -324.57M | 683.52M |
| Financing Cash Flow | 45.63M | -12.12M | 99.29M | 76.23M | 1.66B |
Zhaoke Ophthalmology Ltd. Technical Analysis
Negative
3.17
Price Trends
3.03
Negative
3.17
Negative
3.33
Negative
Market Momentum
-0.11
Positive
29.83
Positive
9.97
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6622, the sentiment is Negative. The current price of 3.17 is above the 20-day moving average (MA) of 2.91, above the 50-day MA of 3.03, and below the 200-day MA of 3.33, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 29.83 is Positive, neither overbought nor oversold. The STOCH value of 9.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6622.
Zhaoke Ophthalmology Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | HK$8.85B | 15.02 | 4.24% | 4.28% | -7.59% | -41.42% | |
54 Neutral | HK$3.51B | -3.96 | -14.53% | ― | -32.12% | -393.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$5.19B | -52.26 | -4.32% | ― | 93.26% | 49.38% | |
47 Neutral | HK$1.45B | -4.01 | -12.64% | ― | -53.85% | 12.23% | |
45 Neutral | HK$924.98M | -7.27 | -15.19% | ― | ― | 20.16% | |
41 Neutral | HK$512.53M | -3.95 | 293.08% | ― | ― | -25.79% |
* Healthcare Sector Average
HK:6622
Zhaoke Ophthalmology Ltd.
2.65
0.31
13.25%
HK:1477
Ocumension Therapeutics
6.40
-0.43
-6.30%
HK:1875
TOT BIOPHARM International Co. Ltd.
4.41
2.61
145.00%
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
3.58
1.06
42.06%
HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H
20.70
-3.77
-15.41%
HK:6978
Immunotech Biopharm Ltd
0.82
-2.27
-73.46%
Zhaoke Ophthalmology Ltd. Corporate Events
Zhaoke Ophthalmology Shareholders Approve All Resolutions at 2026 AGM
May 15, 2026
Zhaoke Ophthalmology Limited reported that all resolutions proposed at its annual general meeting held on May 15, 2026 were approved by shareholders by way of poll. Investors granted the board mandates to repurchase up to 10% of issued shares, iss...
Zhaoke Ophthalmology Renews Related-Party CMO Deal for Eyprotor
Apr 30, 2026
Zhaoke Ophthalmology has renewed its contract manufacturing arrangement with related party Lee’s Pharm Hefei to secure continued production of its ophthalmic drug Eyprotor for commercial sale. The deal is structured through a supplemental ag...
Zhaoke Ophthalmology Sets 2026 AGM to Seek Share Repurchase and Issuance Mandates
Apr 23, 2026
Zhaoke Ophthalmology Limited has called its annual general meeting for May 15, 2026, in Hong Kong, where shareholders will vote on key share capital mandates. The agenda includes proposals to authorize the board to repurchase up to 10% of the comp...
Zhaoke Ophthalmology Moves to Update Articles for Hybrid Meetings and New HK Rules
Apr 15, 2026
Zhaoke Ophthalmology Limited plans to overhaul its articles of association, replacing the existing version with amended and restated articles to align with updated Hong Kong listing and regulatory standards. The move focuses on facilitating hybrid...
Zhaoke Ophthalmology Narrows Core Loss as Revenue Halves in 2025
Mar 25, 2026
Zhaoke Ophthalmology reported a sharp decline in revenue to RMB31.97 million for 2025 from RMB69.32 million in 2024, with gross profit falling to RMB16.05 million from RMB51.80 million, reflecting pressure on its commercial operations. The company...
Zhaoke Ophthalmology Schedules Board Meeting to Approve 2025 Annual Results
Mar 11, 2026
Zhaoke Ophthalmology Limited has scheduled a board meeting for March 25, 2026, to review and approve the annual results for the year ended December 31, 2025, and to authorize their publication. The announcement signals the forthcoming release of t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.